USC biomedical engineers have created “EchoBack CAR T-cells,” smart immune cells that fight cancer up to five times longer than traditional CAR T-cells. This innovation could transform immunotherapy for solid tumors.
These cells are activated by a brief ultrasound pulse at the tumor site and continue working for at least five days compared to just 24 hours for standard CAR T-cells. They respond to tumor signals by producing more cancer-killing molecules and automatically shut down when away from tumors, protecting healthy tissue.
In mouse studies with prostate cancer and glioblastoma, EchoBack CAR T-cells outperformed standard treatments, reduced cell exhaustion, and required fewer treatment sessions — potentially just once every two weeks. Ultrasound provides precise, remote control of therapy.
Researchers aim to expand this approach to breast cancer, retinoblastoma, and other solid tumors.EchoBack CAR T-cells could make cancer treatment safer, more effective, and less burdensome for patients.